Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.33 |
| ▸ | CTRC | Q99895 | 2/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 2/20 | 0.31 |
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
| ▸ | NOS2 | P35228 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2594870 | 0.90 | ALDH1A1 (0.43) | ALDH1A1PRSS1CTRCF2FAAH | |
| SCHEMBL7174440 | 0.88 | ALDH1A1 (0.42) | ALDH1A1PRSS1CTRCF2FAAH | |
| SCHEMBL11431438 | 0.77 | ALDH1A1 (0.41) | ALDH1A1PRSS1CTRCF2NOS3 | |
| SCHEMBL7926747 | 0.75 | HTR2A (0.49) | ALDH1A1KMT2A | |
| SCHEMBL22790519 | 0.75 | ALDH1A1 (0.52) | ALDH1A1PRSS1CTRCF2FAAH | |
| SCHEMBL11428195 | 0.72 | ALDH1A1 (0.37) | ALDH1A1FAAHMAPT | |
| SCHEMBL9436209 | 0.71 | ALDH1A1 (0.44) | ALDH1A1 | |
| SCHEMBL8627491 | 0.70 | FAAH (0.35) | ALDH1A1PRSS1CTRCF2FAAH | |
| SCHEMBL19302160 | 0.70 | — | — | |
| SCHEMBL3259636 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4338466-A | PRECURSORS FOR OLIGOMERS EXHIBITING PROTECTION FOR OXIDATIVE PHOSPHORYLATION OF DEGENERATED MITOCHONDRIA | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE NAVY (US) | 1982-07-06 | — | — | US | claimed |
| US-3962291-A | TOTAL SYNTHESIS OF 11-ALKYL STEROIDS | G. D. SEARLE & CO. (US) | 1976-06-08 | — | — | US | claimed |
| EP-2803358-B1 | 10,10-Dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure | ALLERGAN INC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-9637467-B2 | Treatment of inflammatory bowel disease | ALLERGAN, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| US-9334262-B2 | Methods of treating soft tissue defects | ALLERGAN, INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20160096817-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | ALLERGAN, INC. | 2016-04-07 | — | — | US | disclosed |
| US-9156810-B2 | Treatment of inflammatory bowel disease | ALLERGAN, INC. (US) | 2015-10-13 | — | — | US | disclosed |
| US-9005605-B2 | Compositions and soft tissue replacement methods | ALLERGAN, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-8926963-B2 | Compositions and soft tissue replacement methods | ALLERGAN, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| EP-2814510-A1 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS | ALLERGAN, INC. (US) | 2014-12-24 | — | — | EP | disclosed |
| EP-2814482-A1 | COMPOSITIONS AND IMPROVED SOFT TISSUE REPLACEMENT METHODS | ALLERGAN, INC. (US) | 2014-12-24 | — | — | EP | disclosed |
| US-3984473-A | Stereospecific total steroidal synthesis via substituted C/D-trans indanones | HOFFMANN-LA ROCHE INC. (US) | 1976-10-05 | — | — | US | disclosed |
| US-3979458-A | Production of unsaturated carbocyclic ketones | SYNTEX CORPORATION (PM) | 1976-09-07 | — | — | US | disclosed |
| US-3965138-A | Steroid total synthesis process utilizing a cyanoalkyl A-ring precursor | HOFFMANN-LA ROCHE INC. (US) | 1976-06-22 | — | — | US | disclosed |
| US-3965117-A | Stereospecific total steroidal synthesis via substituted c/d-trans indanones | HOFFMANN-LA ROCHE INC. (US) | 1976-06-22 | — | — | US | disclosed |
| US-3962291-A | TOTAL SYNTHESIS OF 11-ALKYL STEROIDS | G. D. SEARLE & CO. (US) | 1976-06-08 | — | — | US | disclosed |
| US-3950389-A | Stereospecific total steroidal synthesis via substituted C/D-trans indanones | HOFFMANN-LA ROCHE INC. (US) | 1976-04-13 | — | — | US | disclosed |
| US-3931322-A | FROM GAMMA-KETOESTERS AND AN ALKALI METAL ALKOXIDE | HOFFMANN-LA ROCHE INC. (US) | 1976-01-06 | — | — | US | disclosed |
| US-3931322-A | FROM GAMMA-KETOESTERS AND AN ALKALI METAL ALKOXIDE | HOFFMANN-LA ROCHE INC. (US) | 1976-01-06 | — | — | US | disclosed |
| US-3931322-A | FROM GAMMA-KETOESTERS AND AN ALKALI METAL ALKOXIDE | HOFFMANN-LA ROCHE INC. (US) | 1976-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160096817-A1 | TREATMENT OF INFLAMMATORY BOWEL DISEASE | SLC10A2, FABP2, LTB4R2 | ALDH1A1 1092/4885PRSS1 1853/4885CTRC 2978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.